Europe / Sandoz Bolsters its Essential Medicine Manufacturing Capacity
In the wake of the COVID-19 crisis and the subsequent strain placed on medicine supply chains in Europe, Sandoz –…
EUROPE
Pharma Faces / Teresa Rodó, Head of Global Healthcare Operations, Merck
PharmaBoardroom recently sat down with Merck’s EVP and Head of Global Healthcare Operations, Teresa Rodó to…
Roche / Back on Top of The Global Biopharma Rankings
Swiss giant Roche tops Pharmaceutical Executive’s 2020 list of the world’s biggest pharma companies, up…
Data / Switzerland Innovation & Competitiveness Snapshot 2020
In just a few years, Switzerland has fallen from first to fifth place in the Global Competitiveness Index. The…
Data / Belgium Healthcare Snapshot 2020
An overview of health and healthcare in Belgium with data on the country’s leading causes of death,…
News Roundup / French Pharma August 2020
A roundup of some of the latest from French pharma, including Sanofi’s bumper Prinicipia deal, how Unither’s…
Norway / Staking a Claim as a Pharma Research Hub?
Norway, more well-known internationally as an innovation hub for oil & gas and marine biology, is attempting to…
The Long Read / Belgium: The Multifaceted
Squirreled away in the lowlands of North West Europe and somewhat dwarfed by the mighty neighbouring pharmaceutical…
Cell & Gene Therapy Launches / Zolgensma® in Belgium: Lessons Learned
In late 2019 Novartis hit the headlines in Belgium after it refused to grant access to its one-off gene therapy…
In Conversation
Kristel de Bisschop – General Manager, Pierre Fabre Benelux
Pierre Fabre Benelux General Manager Kristel de Bisschop discusses the challenges and opportunities inherent in taking charge of an important affiliate against the backdrop of a group-wide transformation push and a global pandemic. de Bisschop also touches on key product launches in both oncology and dermatology, the synergies between these two business arms, and how COVID-19 has led to a…
Latest Reports
Focus on Belgium
The Long Read: Belgium – The Multifaceted
Squirreled away in the lowlands of North West Europe and somewhat dwarfed by the…
Pharma Faces: Sonja Willems, Janssen Benelux
Belgium is a vitally important country for Johnson & Johnson's…
Read more from Belgium >>
Focus on Romania
Company Spotlight: BMS Romania
With the 2019 acquisition of Celgene – one of the largest pharma acquisition…
Brain Drain: A Ticking Time Bomb for Romanian Healthcare
According to a 2015 United Nations International Migration Report, since Romania…
Read more from Romania >>
Focus on France
French Pharma News Roundup August 2020
A roundup of some of the latest from French pharma, including Sanofi’s bumper…
Sanofi Buys Principia for USD 3.7 Billion as Part of…
Sanofi has agreed a deal to buy out its partner, US biotech company Principia…
Read more from France >>
Focus on Switzerland
Roche: Back on Top of The Global Biopharma Rankings
Swiss giant Roche tops Pharmaceutical Executive's 2020 list of the world's…
Merck’s EUR 250 Million Investment in New Swiss Biotech…
German biopharma giant Merck is investing EUR 250 million in a new Swiss biotech…
Read more from Switzerland >>
Patient Registries / Hungary’s First Steps into Digital Healthcare
After years of planning and collaboration with various stakeholders, in 2017 the Hungarian government launched the…
Value-Based Healthcare / Exploring the Possibilities in Hungary
Among the efforts of Hungarian stakeholders to determine more efficient pricing and reimbursement structures, there…
Pharma Faces / Anna Wienner, IBSA Hungary
As general manager of the Hungarian affiliate of Swiss firm IBSA, Anna Wienner has proven herself to be a motivated…
Ipsen / Problems Pile Up after Further Clinical Setback
These are worrying times for iconic French mid-cap Ipsen. Trials for palovarotene, a treatment for rare bone…
Romania / Europe's Most Challenging Market for Generics?
While the dismal regulatory environment in Romania has negatively affected the innovators with the uncertain and…
Speeding Up Access to Innovation in Portugal
A new regulation is helping Portugal’s market access conditions for pharmaceuticals catch up with those of other…